Multidisciplinary treatment of thoracic fistulous empyema caused by pulmonary infection: a retrospective study
Keywords:
Fistulous empyema, endobronchial occlusion, common bacteria, non-tuberculosis mycobacteria, tuberculosisAbstract
Background: In cases of thoracic empyema, the presence of a fistula is known to be difficult to treat and associated with a poor prognosis. Few reports have described the management of fistulous empyema caused by lung parenchymal infection. The aim of this study was to describe the outcomes of multidisciplinary management of fistulous empyema caused by pneumonia or lung abscess due to common bacteria and mycobacteria.
Methods: Among 108 cases of empyema surgically treated at Kanagawa Hospital over a 10-year period, 14 patients with fistulous empyema due to common bacteria (CBFE) or fistulous empyema due to mycobacteria (MFE) were analyzed. Fistulous empyema due to lung resection was excluded.
Results: Eight out of the 9 patients with CBFE and 4 out of the 5 patients with MFE were male. Patients with CBFE were more likely to be >65 years of age (p=0.052) and to have a poor performance status (p=0.078). The time from onset to first surgical treatment was significantly longer in MFE (median, 5 months; p=0.004). Five patients with CBFE and two patients with MFE underwent open window thoracostomy, while three patients with CBFE and four patients with MFE underwent endobronchial occlusion (EBO). Six patients (66%) with CBFE and 3 patients (60%) with MFE achieved fistula closure. Of the patients who underwent EBO, fistula closure was achieved in 3 (100%) of the patients with CBFE and in 2 (50%) of the patients with MFE. Fistula closure was not achieved in any case with non-tuberculous mycobacteria.
Conclusions: Fistulous empyema caused by common bacteria or Mycobacterium tuberculosis could be cured by surgical treatment and endobronchial intervention with adequate antimicrobial therapy, but fistulous empyema caused by non-tuberculous mycobacteria proved to be intractable. The challenge in the treatment of fistulous empyema due to non-tuberculous mycobacteria is the achievement of bacterial negativity.
References
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Kuwano H, Okumura M, Amano J, et al. Thoracic and cardiovascular surgery in Japan during 2012. Gen Thorac Cardiovasc Surg 2014;62:734-64.
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Okumura M, Doki Y, Endo S, et al. Thoracic and cardiovascular surgery in Japan during 2014. Gen Thorac Cardiovasc Surg 2016;64:665-97.
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H, Okada M, Tangoku A, Doki Y, et al. Thoracic and cardiovascular surgeries in Japan during 2017. Gen Thorac Cardiovasc Surg 2020;68:414-49.
Sugiura Y, Nakamura M, Fujimoto H, Ochiai H, Ohkubo Y, Fusegawa H, et al. An independent prognostic factor in surgical cases of pleural empyema caused by common bacteria is the presence of a fistula. Gen Thorac Cardiovasc Surg 2023. Online ahead of print.
Shen KR, Bribriesco A, Crabtree T, denlinger C, Eby J, Eiken P, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 2017;153:e129-e146.
Davies HE, Davies RJO, Davies CWH, BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax 2010;65:ii41-ii53.
Massera F, Robustellini M, Pona CD, Rossi G, Rizzi A, Rocco G. Open window thoracostomy for pleural empyema complicating partial lung resection. Ann Thorac Surg 2009;87:869-73.
Wotton R, Garner M, Salem A, Buderi S. Is open window thoracostomy the only method to control infection in patients with an empyema following pulmonary resection for primary lung cancer? Interact Cardiovasc Thorac Surg 2021;32:928-32.
Zanotti G, Mitchell JD. Bronchopleural Fistula and empyema after anatomic lung resection. Thorac Surg Clin 2015;25:421-7.
Asamura H, Naruke T, Tsuchiya R, Goya T, Kondo H, Suemasu K. Bronchopleural fistulas associated with lung cancer operations. Univariate and multivariate analysis of risk factors, management, and outcome. J Thorac Cardiovasc Surg 1992;104:1456-64.
Okuda M, Go T, Yokomise H. Risk factor of bronchopleural fistula after general thoracic surgery: review article. Gen Thorac Cardiovasc Surg 2017;65:679-85.
Tsukioka T, Izumi N, Mizuguchi S, Kyukwang C, Komatsu H, Toda M, et al. Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ratio in pathological stage IIIA (N2-positive) non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg 2018;66:716-22.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
Hu Y, Shen J, Liu R, Feng ZM, Zhang CN, Ling L, et al. Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis. Int J Biol Markers 2018;33:372-8.
Lee SI, Ko K-P, Choi CH, Park C-H, Park KY, Son KH. Does the prognostic nutritional index have a predictive role in the outcomes of adult cardiac surgery? J Thorac Cardiovasc Surg 2020;160:145-53.e3.
Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest 2014;145:848-55.
Nakao M, Muramatsu H, Arakawa S, Sakai Y, Suzuki Y, Fujita K, et al. Immunonutritional status and pulmonary cavitation in patients with tuberculosis: A revisit with an assessment of neutrophil/lymphocyte ratio. Respir Investig 2019;57:60-6.
Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis 2016;22:1116-7.
Lai S-W, Lin C-L, Liao K-F. Population-based cohort study investigating the correlation of diabetes mellitus with pleural empyema in adults in Taiwan. Medicine (Baltimore) 2017;96:e7763.
Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007;30:2251-7.
Okui M, Kohno M, Hasegawa N, Kamiyama I, Ohtsuka T. Intractable pneumothorax treated with endobronchial Watanabe spigots. J Bronchology Interv Pulmonol 2016;23:350-3.
Flora AS, Aragaki-Nakahodo A, Benzaquen S. Endobronchial valve placement for persistent air leaks secondary to pulmonary infections. J Bronchology Interv Pulmonol 2021;28:47-52.
Penhallow K. A review of studies that examine the impact of infection on the normal wound-healing process. J Wound Care 2005;14:123-6.
Robson MC, Stenberg BD, Heggers JP. Wound healing alterations caused by infection. Clin Plast Surg 1990;17:485-92.
Shiraishi Y, Katsuragi N, Kita H, Tominaga Y, Hiramatsu M. Different morbidity after pneumonectomy: multidrug-resistant tuberculosis versus non-tuberculous mycobacterial infection. Interact Cardiovasc Thorac Surg 2010;11:429-32.
World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance. 2013. Accessed: cited 2023 Apr 29. Available from: https://www.who.int/publications/i/item/9789241505482
Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Pneumonectomy for nontuberculous mycobacterial infections. Ann Thorac Surg 2004;78:399-403.
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Minatoya K, Sato Y, Toh Y, Abe T, et al. Thoracic and cardiovascular surgeries in Japan during 2019: Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2023;71:595-628.
Published
Issue
Section
License
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
